Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733) - guidance

NICE recommend inclisiran as an option for primary hypercholesterolaemia/mixed dyslipidaemia as an adjunct to diet in adults, if there is history of a specific CV event, & where the LDL-C concentrations are persistently above 2.6mmol/L despite max tolerated lipid lowering therapy

SPS commentary:

Specifically, inclisiran is restricted to use where:

  • There is a history of any of the following cardiovascular events:
    • acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
    • coronary or other arterial revascularisation procedures
    • coronary heart disease
    • ischaemic stroke or
    • peripheral arterial disease


  • Low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is:
    • maximum tolerated statins with or without other lipid-lowering therapies or,
    • other lipid-lowering therapies when statins are not tolerated or are contraindicated


National Institute for Health and Care Excellence